Drug therapy of tardive dyskinesia.
D000367:Age Factors; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001921:Brain / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D010208:Papaverine / Q000627:therapeutic use; D010276:Parasympatholytics / Q000009:adverse effects; D010277:Parasympathomimetics / Q000627:therapeutic use; D010640:Phenothiazines / Q000627:therapeutic use; D010868:Pimozide / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects; D012110:Reserpine / Q000627:therapeutic use; D013747:Tetrabenazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010276:Parasympatholytics; D010277:Parasympathomimetics; D010640:Phenothiazines; D011954:Receptors, Dopamine; D010868:Pimozide; D012110:Reserpine; D008094:Lithium; D010208:Papaverine; D006220:Haloperidol; D004298:Dopamine; D013747:Tetrabenazine